Indication intelligence, analysis and sector perception

Histogenics (HSGX) Jumps 40.79% in pre-market

January 12, 2017 8:14am

On robust volume in response to its announcement of positive results from NeoCart’s P1 & 2 studies.

The results were just published in the online version of the American Journal of Sports Medicine.

In a pooled analysis, 29 patients with symptomatic full thickness cartilage lesions in the knee joint were treated with NeoCart, a tissue-engineered implant created with the patient's own cartilage cells. 21 of the patients were evaluable at the final time point of the 60-month follow-up period.

The Bottom Line; Analyses by MRI showed significant improvement in cartilage quality from month 3 to 24 with stabilization and maturation from month 24 to 60; NeoCart was shown that it was safe and effective through five years of follow-up and that it delivered statistically significant improvements on virtually all pain and functional endpoints as early as month 3 with sustained benefits though month 60.

As I had stated, HSGX is always the come-back share.

NeoCart is currently in P3 development for the first-line treatment of full thickness knee cartilage defects in adults.

HSGX closed DOWN -$0.02 to $1.52 and is UP +0.62 or +40.79%

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 58 min ago
RegMed Investors’ (RMi) pre-open: finding our way

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.